Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025GlobeNewsWire • 08/05/25
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value InvestorsZacks Investment Research • 07/14/25
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology ConferenceGlobeNewsWire • 06/20/25
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain StockZacks Investment Research • 06/19/25
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TVGlobeNewsWire • 06/09/25
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced MomentumZacks Investment Research • 06/03/25
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint TherapeuticsGlobeNewsWire • 05/30/25
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/15/25
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/14/25
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesGlobeNewsWire • 05/13/25
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025GlobeNewsWire • 05/07/25
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceGlobeNewsWire • 05/07/25
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerGlobeNewsWire • 04/01/25
Fortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/31/25
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesGlobeNewsWire • 03/28/25
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/26/25
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of RosaceaGlobeNewsWire • 03/24/25
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025GlobeNewsWire • 03/19/25
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI PlatformGlobeNewsWire • 03/17/25